Donor Lymphocyte Infusion

PROCEDURE20 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Lund University Hospital, Assistance Publique - Hôpitaux de Paris, Carlos Graux, MD, PhD, University of California, San Francisco

Conditions

AMLAcute LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoid LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAdult T-Cell Leukemia/LymphomaAllogeneic Hematopoietic Stem Cell Transplantation

Early Phase 1

Haploidentical Stem Cell Transplantation in Neuroblastoma

Lund University HospitalNeuroblastoma

Start: 2005-08-31End: 2022-12-31Target: 15Updated: 2021-02-21

Phase 1

Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion

CompletedNCT00987987

Assistance Publique - Hôpitaux de ParisHematologic Neoplasms, Relapse

Start: 2005-12-31End: 2009-12-31Updated: 2011-01-24

Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation

CompletedNCT01086735

Assistance Publique - Hôpitaux de ParisHematological Malignancy

Start: 2010-02-28End: 2012-11-30Updated: 2013-01-14

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

TerminatedNCT03537599

Sumithira VasuMinimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia +1

Start: 2020-01-10End: 2022-02-03Updated: 2025-05-21

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Active, not recruitingNCT03597594

St. Jude Children's Research HospitalSevere Combined Immunodeficiency

Start: 2021-09-02End: 2028-07-01Updated: 2025-07-01

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

RecruitingNCT05327023

National Cancer Institute (NCI)Hematologic Neoplasms

Start: 2022-05-23End: 2029-07-02Target: 430Updated: 2026-01-26

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

SuspendedNCT06158100

Antonio M Jimenez JimenezAcute Myeloid Leukemia

Start: 2024-12-04End: 2027-12-31Target: 25Updated: 2025-08-06

Phase 2

Post Transplant Donor Lymphocyte Infusion

TerminatedNCT00167180

Masonic Cancer Center, University of MinnesotaAML, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic +4

Start: 2004-01-31End: 2018-12-24Updated: 2019-07-30

Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia

CompletedNCT01025778

Lund University HospitalAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2009-12-31End: 2012-12-31Updated: 2021-02-21

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

CompletedNCT02017457

Carlos Graux, MD, PhDAcute Myelogenous Leukemia, Myelodysplastic Syndrome

Start: 2013-12-31End: 2019-11-30Updated: 2019-12-10

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

CompletedNCT02458235

University of California, San FranciscoAcute Lymphoid Leukemia, Acute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia +1

Start: 2015-06-02End: 2019-03-15Updated: 2020-10-12

MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

CompletedNCT02673008

Nanfang Hospital, Southern Medical UniversityDonor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation, Minimal Residual Disease +1

Start: 2016-01-31End: 2019-12-31Updated: 2020-02-25

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

CompletedNCT03032783

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematopoietic and Lymphoid Cell Neoplasm

Start: 2017-01-31End: 2025-12-02Updated: 2026-01-29

Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant

Peking University People's HospitalAcute Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Donor Lymphocyte Infusion +3

Start: 2017-03-01End: 2021-10-01Target: 40Updated: 2020-03-10

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

CompletedNCT03712878

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematopoietic and Lymphoid Cell Neoplasm

Start: 2018-09-19End: 2025-03-19Updated: 2025-08-22

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

TerminatedNCT04582864

Washington University School of MedicineRelapsed Acute Myeloid Leukemia

Start: 2021-05-20End: 2024-07-26Updated: 2024-12-06

Two Step Haplo With Radiation Conditioning

RecruitingNCT05031897

Thomas Jefferson UniversityAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma +14

Start: 2021-10-25End: 2032-04-30Target: 63Updated: 2025-10-30

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

WithdrawnNCT06297629

M.D. Anderson Cancer CenterAllogeneic Stem Cell Transplantation

Start: 2024-07-01End: 2024-07-11Updated: 2026-02-24

Unknown Phase

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

CompletedNCT00167167

Masonic Cancer Center, University of MinnesotaAML, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic +1

Start: 1995-12-31End: 2006-01-31Updated: 2017-11-29

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

RecruitingNCT05772273

The First Affiliated Hospital of Soochow UniversityAcute Myeloid Leukemia

Start: 2023-03-15End: 2026-12-31Target: 43Updated: 2025-11-21

Related Papers

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Blood2024-11-05

Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph– high-risk B-cell acute lymphoblastic leukemia

Chinese Medical Journal2021-11-309 citations

The combination of clofarabine, etoposide, and cyclophosphamide shows limited efficacy as a bridge to transplant for children with refractory acute leukemia: results of a monitored prospective study

Pediatric Hematology and Oncology2020-11-051 citations

Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data.

2020-03-1244 citations

Azacitidine Administration Following Hematopoietic Stem Cell Transplantation Is Safe and Feasible in Children with Acute Leukemia

Blood2016-12-024 citations